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Background: Current evidence suggests that high concentrations of pro-inflammatory markers are associated with
bipolar disorder characterized by severe impairment during inter-episodic periods, reduced treatment response and
persistent subsyndromal symptoms. We tested whether persistent subsyndromal symptoms in euthymic bipolar
patients were associated with markers of an ongoing chronic pro-inflammatory process.
Methods: Forty-five euthymic bipolar patients (22 with subsyndromal symptoms (BD+) and 23 without
subsyndromal symptoms (BD-) and 23 well controls (WC) were recruited for assessment of soluble tumor necrosis
factor receptor-1 (sTNF-R1), soluble interleukin-6 receptor (sIL-6R) and soluble interleukin-2 receptor (sIL-2R)
concentrations. Soluble cytokine receptor concentrations were assessed using enzyme-linked immunosorbent assay.
Results: In comparison to WC, sTNF-R1 concentration was higher in both BD- and BD+ (age and sex adjusted
standardized β, respectively: β= 0.34, p = 0.012 and β= 0.41, p = 0.003). Similarly, compared to WC, sIL-6R
concentration was higher in both BD- and BD+ (age and sex adjusted standardized β, respectively: β= 0.44,
p = 0.001 and β= 0.37, p = 0.008). There was no difference between BD- and BD+ in the concentration of either
sTNF-R1 or sIL-6R; plasma concentration of sIL-2R was not analyzed as 75% percent of the samples were
non-detectable.
Conclusions: Although bipolar patients present with a pro-inflammatory shift compared to well controls,
subsyndromal symptoms are not associated with additive increasing effects. Longitudinal studies with larger
samples are required to clarify the relationship between illness course and inflammatory markers in bipolar disorder.
Keywords: Bipolar disorder, Cytokine, Interleukin, Inflammation, Tumor necrosis factor, Euthymic, Subsyndromal,
Staging, BiomarkerBackground
Bipolar disorder (BD) has long been considered an epi-
sodic illness characterized by complete symptomatic re-
covery during inter-episodic periods. However, a growing
body of evidence shows that the rate of inter-episodic
morbidity in the form of subsyndromal symptoms is much
higher than previously thought [1,2]. Therefore, early rec-
ognition and treatment of subsyndromal symptoms* Correspondence: sguloksuz@yahoo.com
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reproduction in any medium, provided the orrepresents an important target for clinicians, given
associations with increased risk of relapse, decrement
in functioning and cognitive dysfunction [2-4]. However,
treatment alternatives are limited for the patients with
subsyndromal symptoms, many of whom do not respond
adequately to conventional therapies [4].
Recent data indicate that immune modulation may
play an important role in the pathophysiology of BD,
with the possibility of novel mechanistic options for
treatment [5,6]. Alterations in cytokine functioning may
represent a fitting theoretical perspective underlying
possible immuno-modulatory treatment approaches.
Current knowledge about cytokines points to regulatorytd. This is an Open Access article distributed under the terms of the Creative
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role in the immune system [7]. Studies comparing cyto-
kine concentrations in bipolar patients and healthy con-
trols have demonstrated that mania and depression
show characteristics of pro-inflammatory states with
higher concentrations of pro-inflammatory cytokines
and lower concentrations of anti-inflammatory cytokines
[6]. Additionally, up-regulation of the immune system
appears to resolve during euthymia [8-11]. In the light of
this evidence, inflammation in BD may be regarded as a
state arising during acute episodes rather than a trait
influencing longitudinal course of illness. However, find-
ings of studies far from consistent; selection of heteroge-
neous study populations may represent an important
factor underlying between-study discrepancies. For ex-
ample, previous work by our group suggests that con-
centrations of tumor necrosis factor-alpha (TNF-α), a
major pro-inflammatory cytokine, may represent hetero-
geneity between euthymic BD patients in association
with longitudinal measures of lithium response [12]. In-
deed, the use of inflammatory markers for staging BD
has been proposed [13,14]. According to this model,
high concentrations of TNF-α are associated with
advanced stages of BD with severe impairment during
inter-episodic periods, reduced treatment response and
ongoing subsyndromal symptoms.
Therefore, the current study aimed to determine if
there is an ongoing chronic pro-inflammatory process in
euthymic bipolar patients with subsyndromal symptoms,
characterised by higher concentrations of soluble tu-
mor necrosis factor receptor-1 (sTNF-R1), soluble
interleukin-6 receptor (sIL-6R) and soluble interleukin-2
receptor (sIL-2R), all of which are thought to represent
reliable markers of inflammatory activity and all of
which have been widely investigated in BD. Moreover, a
recent meta-analysis, examining a wide range of cyto-
kines and soluble cytokine receptors, shows evidence of
higher concentrations of sTNF-R1 and sIL-2R in bipolar
patients [15]. To this end, the study sampling frame pro-
vided comparisons between three groups: (i) euthymic
bipolar patients with subsyndromal symptoms (BD+); (ii)
euthymic bipolar patients without subsyndromal symp-
toms (BD-); (iii) well controls (WC).
Methods
Study population
A total of 45 patients, who met the DSM-IV criteria for
BD-I, were recruited among long-term follow-up outpa-
tients of the Rasit Tahsin Mood Disorders Outpatient
Unit (RTMDOU) of the Bakirkoy Research and Training
Hospital for Psychiatry, Neurology, and Neurosurgery.
All of the 910 registered BD patients at RTMDOU con-
tinue to be evaluated with standardized medical forms
based on a nation-wide mood disorders follow-upprogram named SKIP-TURK [16]. The SKIP-TURK
form, which is similar to the “Clinical Monitoring Form”
(CMF) used in the Systematic Treatment Enhancement
Program for Bipolar Disorder (STEP-BD) [17], was put
into use to (i) assess the clinical characteristics of BD
patients (e.g. polarity of the first episode, duration of ill-
ness) and (ii) to evaluate illness course of BD patients
over clinical follow-up. The diagnosis of the patients was
confirmed both by clinical interview and by the SKIP-
TURK procedure. Of the patients, 23 were euthymic
without subsyndromal symptoms (BD-). BD+ status was
defined a priori on the basis of consensus decisions in
SKIP-TURK; thus, 22 patients were in a euthymic state
with at least 2 moderate affective symptoms coded in
the SKIP-TURK form at 2 consecutive clinical evalua-
tions during a follow-up period of minimally two
months, however without meeting criteria for a full
affective episode as defined in DSM-IV. All the patients
were medicated either with mono-therapy of either of
mood stabilizer, an antipsychotic or an antidepressant,
or with combination therapy combining any of these.
Twenty-three well controls were also recruited from
the hospital staff, reflecting the general population socio-
economic strata. A clinical psychiatrist (TC) evaluated
well controls with a standard clinical psychiatric inter-
view to screen for psychiatric disorders. The exclusion
criterion for well controls was presence of any current
Axis I psychiatric disorder. The study was approved by
the standing Medical Ethics Committee of Bakirkoy Re-
search and Training Hospital for Psychiatry, Neurology,
and Neurosurgery, and carried out in accordance with
the Declaration of Helsinki. All the participants gave
informed consent before enrolment in the study.
Information including medical history, physical exam-
ination, laboratory evaluation including complete blood
count, blood chemistry, urinalysis, thyroid function test
and electrocardiogram were obtained from all partici-
pants in order to evaluate potential exclusion criteria.
The exclusion criteria for all participants were any aller-
gic disease, an infectious disease within the last four
weeks, use of any potentially immunosuppressive drug
such as corticosteroids, non-steroid anti-inflammatory
drugs within the last four weeks, pregnancy or breast-
feeding, current use of alcohol at more than 5 standard
units per week, current intake of caffeine at more than
three cups of coffee per day, and current use of tobacco
at more than 10 cigarettes a day.
Enzyme-linked immunosorbent assays (ELISAs) for
sTNF-R1 and sIL-6R
The blood samples were obtained between 08.00 AM
and 10.00 AM and were collected in heparin vacuum
tubes. The blood samples were immediately centrifuged
for 10 min at 3000 rpm and the plasma samples were
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R1 concentrations in the plasma were assessed using an
ELISA kit (BioSource International, Inc, Camarillo, USA)
according to the manufacturer’s directions. Plasma sam-
ples were diluted 1:100 for sIL-6R and 1:4 for sIL-2R de-
tection in the sample using diluent buffer provided with
the ELISA kit. Supplied standards were used to generate
the standard curves. The samples and standards were ap-
plied to wells. Unbound protein was removed by washing,
and biotin-conjugate, followed by horseradish peroxidase-
conjugated streptavidin, were added in a step-wise man-
ner. After the color reaction with substrate, the optical
density was recorded at 450-nm wavelength with an
automated ELISA reader. The absorbance at 450 nm was
converted to picograms per millilitre (pg/ml) for sIL-6R,
sIL-2R and nanograms per millilitre (ng/ml) for sTNF-R1.
The minimal detection limits were: for sIL-2R : 16pg/ml,
for sIL-6R : 8 pg/ml and for sTNF-R1 : 0.03 ng/ml.Statistical analysis
Plasma concentrations of sIL-6R and sTNF-R1 were de-
tectable in all participants. Plasma concentration of sIL-






Age at onset (years)
Onset episode (mania/depression)
Duration of illness (years)




Total number of episodes per year





MS + AP + AD
Duration of ongoing subsyndromal symptoms (months)
Subtype of ongoing subsyndromal symptoms (depressive/
manic/mixed)
WC: well controls, BD-: euthymic bipolar patients without subsyndromal symptoms,
MS: Mood stabilizer, AP: Antipsychotic, AD: Antidepressant.
aChi square.
bOne-way ANOVA.
ct test.non-detectable. Demographic, clinical and treatment
characteristics were analyzed by one-way ANOVA, two
tailed t-test and chi-square test as indicated. Associations
between sTNF-R1 and sIL-6R concentrations and a priori
selected confounders (sex, age) were assessed using
Pearson’s product-moment correlation for age and one-
way ANOVA for sex. Pearson’s product-moment correl-
ation was also used to analyze the association between
duration of illness and soluble cytokine receptor con-
centrations. Associations between the three groups (WC,
BD-, BD+) and approximately normally distributed sTNF-
R1 and sIL-6R concentrations were expressed as standar-
dized regression coefficients (β) from multiple regression
procedures with sTNF-R1 and sIL-6R as dependent vari-
able and dummy variables of the three groups as inde-
pendent variable, the WC group serving as reference.
Two-sided statistical significance was set at p < 0.05.
STATA version 12.0 (STATA Corporation, College Station,
TX, USA) was used to carry out the statistical analyses.Results
Table 1 lists the demographic, clinical and treatment
characteristics. Compared to BD-, BD+ had a greaterC BD- BD+ P-value
= 23) (n = 23) (n = 22)
) or n (%) Mean (SD) or n (%) Mean (SD) or n (%)
(52.2) 13 (56.5) 12 (54.5) 0.957a
(5.21) 34.61 (7.28) 36.86 (7.03) 0.034b
22.13 (6.37) 21.64 (6.21) 0.793c
15 (65.2) / 8 (34.8) 11 (50) / 11 (50) 0.302a
12.48 (7.23) 15.23 (7.65) 0.222c
4.69 (3.08) 8.95 (6.21) 0.005c
2.96 (2.14) 4.09(4.62) 0.293c
1.13 (1.79) 3.45 (2.70) 0.001c
0.09 (0.29) 0.45 (1.22) 0.168c
0.35 (0.17) 0.55 (0.23) 0.001c
10 (43.5) 10 (45.5) 0.894a
0.006a
9 (39.13) 1 (4.55)
12 (52.17) 13 (59.09)




BD+: euthymic bipolar patients with subsyndromal symptoms,
Figure 1 Box-plot of plasma sTNF-R1 concentration in WC,
BD- and BD+. Median levels are indicated by horizontal lines.
WC: well controls, BD-: euthymic bipolar patients without
subsyndromal symptoms, BD+: euthymic bipolar patients with
subsyndromal symptoms.
Figure 2 Box-plot of plasma sIL-6R concentration in WC,
BD- and BD+. Median levels are indicated by horizontal lines.
WC: well controls, BD-: euthymic bipolar patients without
subsyndromal symptoms, BD+: euthymic bipolar patients with
subsyndromal symptoms.
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depressive episodes (t(43) = 3.41, p = 0.001) and episodes
per year (t(43) = 3.44, p = 0.001). There were no other
differences between BD+ and BD- in terms of clinical
characteristics.
Age was associated with both sTNF-R1 concentration
(r= 0.30, p = 0.013) and sIL-6R concentration (r= 0.25,
p = 0.038). There was no strong or significant associa-
tion between sex and either sTNF-R1 concentration
(F(1,66) = 0.04, p = 0.835) or sIL-6R concentration
(F(1,66) = 0.02, p = 0.877). The mean sTNF-R1 concentra-
tion was 1.26 (SD= 0.74), 2.31 (SD= 1.13) and 2.62 (SD=
1.64) ng/ml in WC, BD- and BD+, respectively
(Figure 1). The mean sIL-6R concentration was 116.12
(SD= 48.46), 192.04 (SD= 72.69) and 184.78 (SD= 82.62)
pg/ml in WC, BD- and BD+, respectively (Figure 2). In
comparison to WC, sTNF-R1 concentration was higher
in BD- and BD+ (uncontrolled standardized β, respect-
ively: β= 0.37, p = 0.005 and β= 0.48, p < 0.001; age and
sex adjusted standardized β, respectively: β= 0.34,
p = 0.012 and β= 0.41, p = 0.003). There was no difference
between BD- and BD+ in sTNF-R1 concentration (un-
controlled standardized β: β= 0.10, p = 0.403; age and sex
adjusted standardized β: β= 0.07, p = 0.559). In compari-
son to WC, sIL-6R concentration was higher in BD- and
BD+ (uncontrolled standardized β, respectively: β= 0.47,
p < 0.001 and β= 0.42, p = 0.001; age and sex adjusted
standardized β, respectively: β= 0.44, p = 0.001 and
β= 0.37, p = 0.008). There was no difference between
BD- and BD+ in sIL-6R concentration (uncontrolled
standardized β: β= -0.05, p = 0.726; age and sex adjusted
standardized β: β= -0.08, p = 0.587). There was no strong
or significant association between duration of illness
and either sTNF-R1 concentration (r= 0.20, p = 0.183) or
sIL-6R concentration (r= 0.08, p = 0.585).
Discussion
This study demonstrated that there were no differences
between BD- and BD+ in terms of sTNF-R1 and sIL-6R
concentrations. However, sTNF-R1 and sIL-6R concen-
trations were higher in both BD- and BD+ in compari-
son to WC.
Our findings are in line with a previous study report-
ing higher concentrations of sTNF-R1 in euthymic BD
patients compared to controls [18,19]. It has been sug-
gested that soluble cytokine receptors may better reflect
the activity of the cytokines in question, given that they
are detectable in plasma even when cytokine concentra-
tions are undetectable [18]. Thus, it is plausible to think
of soluble cytokine receptors as more reliable markers of
activity. In the light of this evidence, both sTNF-R1 and
sIL-6R can be considered as markers reflecting pro-
inflammatory activity. Both TNF-α and IL-6 are primary
regulators of pro-inflammatory process due to theirinitiating roles in the inflammatory cascade of the acute
phase response [7]. They have the ability of affecting
various cells and therefore are regarded as possessing
pleiotropic properties. It has been demonstrated that the
degradation of tryptophan (TRP) by the indoleamine
2,3-dioxygenase (IDO) enzyme is mainly induced by in-
terferon gamma (IFN-γ), but also, to a degree, by TNF-α
and IL-6 [20]. Induced IDO activity causes degradation
of TRP, which serves as a precursor for serotonin. More-
over, induced IDO activity leads to the formation of
neurotoxic metabolites, 3-hydroxykynurenine and qui-
nolinic acid [21]. Several studies have shown an associ-
ation between IDO activation and mood disorder,
particularly unipolar depression [20]. Recently, the TNF-
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ing the pathophysiology of BD [6,22]. TNF-α exerts its
effects via the cell surface receptors called TNFR1 and
TNFR2. The effect of TNFR2 is negligible to TNFR1,
since TNFR1 is expressed in most cells, whereas TNFR2
is expressed only in hematopoietic cells. TNFR1 med-
iates apoptosis, cytokine production and activation of
nuclear factor kappa B (NF-κB), which induces tran-
scription of cell survival genes (i.e. cellular inhibitors of
apoptosis (cIAP), B-cell lymphoma 2 (Bcl-2) family) [6].
It has been postulated that there is a shift towards apop-
tosis during mood episodes and that this shift arises
from increased TNF-α concentration and cessation of
NF-κB neuronal translocation due to decreased brain-
derived neurotrophic factor (BDNF) and nerve growth
factor (NGF) [22]. On balance, the TNF-α system may
be considered an important factor playing a role in the
regulation of neuroplasticity. Moreover, the notion of
TNF-α as a trait marker of BD has some validity given
evidence of higher TNF-α concentration in patients with
BD than in healthy controls, evidence of effects of TNF-
α antagonists on mood symptoms and effects of psycho-
tropics on TNF-α [5,6]. However, it is still premature to
count TNF-α as a trait marker of BD due to the influ-
ence of several confounding factors, particularly the use
of medication, on the immune system. Likewise, the
results of our study should be interpreted carefully con-
sidering medication use as a potential confounder [23].
Controlling for this was not possible, as only patients
used medication, resulting in collinearity. Recent studies
showing no difference between medicated euthymic BD
patients and well controls in terms of TNF-α and IL-6
concentrations contradict the current findings [8,10,11,24].
The conclusion is that additional studies evaluating inflam-
matory markers in the euthymic state, ideally comparing
medication-free BD patients and matched controls in large
samples, are still needed in order to clarify if ongoing in-
flammation is a trait in BD.
According to the model for staging BD with the use of
biomarkers, progression through later stages with social
and cognitive dysfunction and persistent subsyndromal
symptoms in the inter-episode period is associated with
increased oxidative stress and inflammation, which can
be demonstrated by high 3-nitrotyrosine and TNF-α
concentrations [13,14]. This model stages BD in five cat-
egories according to clinical features: Latent Stage is
defined by positive family history of mood disorders,
subthreshold mood or anxiety symptoms; Stage 1 is
defined by euthymic periods without overt psychiatric
symptoms; Stage 2 is defined by symptoms during inter-
episodic periods and comorbid psychiatric disorders;
Stage 3 is defined by marked impairment in cognition
and functioning; Stage 4 is defined by need of a caregiver
in daily life due to severe impairment in cognition andfunctioning [13]. The patients with subsyndromal symp-
toms in our study had persistent symptoms during
euthymia, and experienced a greater number of episodes.
Thus, they can be considered as patients presenting at a
later stage of illness than the group of patients without
subsyndromal symptoms. However, we did not find any
differences between these two groups in terms of sTNF-
R1 and sIL-6R concentrations. In their evaluation of
brain-derived neurotrophic factor and cytokines in early
and late stage BD patients, Kauer-Sant’Anna and collea-
gues demonstrated that TNF-α concentration remained
higher in late stage patients even after controlling for
subsyndromal symptoms [25]. Consequently, they
propose that higher TNF-α concentration in the later
stages of illness may be due to the cumulative effect of
past mood episodes or the cumulative effect of pro-
inflammatory shifts throughout the course of illness,
rather than the effect of subsyndromal symptoms. In ac-
cordance with this finding, the current analysis confirms
that subsyndromal symptoms have minimal effect on
cytokine concentrations. Nevertheless, we do not under-
estimate the cumulative effect of ongoing subsyndromal
symptoms in patients with advanced duration of illness.
BD+ patients had a greater number of episodes per year,
which can be counted as an identifier for poor prognosis
in the future. Thus, it is also plausible to think that pro-
inflammatory shifts may become more evident later in
the course of illness in BD+ compared to BD-. Alterna-
tively, BD- and BD+ could belong to same stage, in con-
trast to what was hypothesized. An in-depth evaluation
of social and cognitive functioning could have provided
more variables for empirical staging.
To the best of our knowledge, this is the first study
investigating immune changes in subsyndromal BD
patients. Although our analyses focused on potential
inflammatory markers of subsyndromal symptoms in
BD-I, no actual associations were presented between
inflammatory markers and specific symptoms. Instead,
we relied on group-level comparisons of patients with
and without subsyndromal symptoms. To the degree
that these groups differ in other aspects other than
symptomatology, results could have been confounded.
Therefore, follow-up research focusing on comparisons
at the symptom level in larger samples is required. Al-
though the study had the benefit of recruiting patients
with subsyndromal symptoms with the help of standar-
dized assessments in a specialized mood disorders out-
patient unit, the definition for subsyndromal state
recommended by the International Society of Bipolar
Disorder (ISBD) could have been measured more pre-
cisely [26]. However, there was no consensus on the
definition of subsyndromal states when the study re-
cruitment was initiated. Moreover, the cross-sectional
design of the study limits our further prediction about
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the long term. It is also important to emphasize that we
were unable to assess body mass index as a potential
confounder. Only soluble receptors of TNF-α and IL-6
were assessed, which are the most studied cytokines in
BD and considered as molecular targets [6,15,22]. Never-
theless, evaluation of additional inflammatory markers
could provide the opportunity of interpreting the find-
ings in more detail. All patients were on medication. As
psychotropics (i.e. lithium) may impact on cytokine con-
centrations [9,12,23], this could have confounded the
results. Given the fact that almost all patients in this
small study had unique, non-overlapping, treatment mo-
dalities (i.e. different combinations of medications and/
or different doses), it was impossible to group according
to treatment modality in detail and describe medication-
related effects in the patient sample. Moreover, previous
work suggests that medications have different, some-
times interacting effects on immune mediators [23]. Al-
though it could be argued that medication equivalents
might have been used in analyses within the patient
group, this method can only be applied to antipsycho-
tics. Furthermore, caution must be taken when using
this methodology, since medication equivalents reflect
efficacy rather than biological mechanisms. Thus, it was
decided not to analyze the effect of each separate medica-
tion on immune mediators in this relatively small sample.
This is a limitation. On the other hand, eliminating this
possibly confounding effect is nearly impossible given the
fact that augmentation strategies, resulting in patient-
unique medication mixes, are routine practice in the treat-
ment of bipolar disorder [15]. The cross-sectional design
of the study also prevented us to evaluate the effects of
earlier, currently discontinued treatment. Given the possi-
bility of residual confounding by medication, and the diffi-
culties in disentangling confounding by medication within
patient-specific polypharmacy approaches, follow-up
semi-experimental studies are required to settle this issue.
Finally, the sample size of the study was relatively small,
which had the inherent risk of type-II error.
Conclusions
Despite its preliminary character, findings of our study
appear to indicate that subsyndromal symptoms do not
influence sTNF-R1 and sIL-6R concentrations. Never-
theless, longitudinal studies with larger samples are
required in order to clarify the relationship between ill-
ness course and inflammatory markers in BD.
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